Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2010

01.05.2010 | Urologic Oncology

The Diminishing Role of Transurethral Resection of the Prostate

verfasst von: Ray M. Merrill, PhD, MPH, Bradley D. Hunter, BA

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

This study provides an update of patterns in transurethral resection of the prostate (TURP) rates in the United States and the extent of TURP-detected prostate cancer incidence rates.

Methods

Analyses are based on data from the National Hospital Discharge Survey, the Surveillance, Epidemiology, and End Results Program, and the U.S. Census Bureau for the years 1996 through 2006.

Results

TURP procedure rates were 6, 14, and 18 times greater in men aged 60 to 69, 70 to 79, and ≥80 years compared with men aged 50 to 59, respectively. During 1996–2006, the estimated annual percentage change in TURP rates was −10.5 (95% confidence interval [95% CI] −14.1 to −6.7) for ages 50 to 59, −7.4 (95% CI −9.2 to −5.6) for ages 60 to 69, −6.2 (95% CI −7.6 to −4.8) for ages 70 to 79, and −7.7 (95% CI −9.5 to −5.8) for ages ≥80 years. TURP-detected prostate cancer incidence rates were 2, 7, and 17 times greater in men aged 60 to 69, 70 to 79, and ≥80 years compared with men aged 50 to 59, respectively. The estimated annual percentage change in trend was −17.8 (−20.6, −15.0) for ages 50 to 59, −14.8 (−16.6, −13.0) for ages 60 to 69, −10.8 (−12.0, −9.7) for ages 70 to 79, and −8.2 (−10.0, −6.5) for ages ≥80 years. Trends in prostate cancer incidence rates peaked in 2002 and decreased thereafter. Some of the decreasing trend in rates among older age groups is because of a decrease in TURPs and consequently a decrease in incidental TURP-detected cases.

Conclusions

TURP procedure rates and incidental TURP-detected prostate cancer incidence rates have declined and will likely continue to decline in the future.
Literatur
1.
Zurück zum Zitat Andrews GS. Latent carcinoma of the prostate. J Clin Pathol. 1949;2:197.CrossRef Andrews GS. Latent carcinoma of the prostate. J Clin Pathol. 1949;2:197.CrossRef
2.
Zurück zum Zitat Edwards CN, Steinthorsson E, Nicholson D. An autopsy of latent prostatic cancer. Cancer. 1953;6:531.CrossRefPubMed Edwards CN, Steinthorsson E, Nicholson D. An autopsy of latent prostatic cancer. Cancer. 1953;6:531.CrossRefPubMed
3.
Zurück zum Zitat Hirst AE Jr, Bergman RT. Carcinoma of the prostate in men 80 or more years old. Cancer. 1954;7:136.CrossRefPubMed Hirst AE Jr, Bergman RT. Carcinoma of the prostate in men 80 or more years old. Cancer. 1954;7:136.CrossRefPubMed
4.
Zurück zum Zitat Whitmore WF Jr. Symposium of hormones and cancer therapy hormone therapy in prostatic cancer. Am J Med. 1956;21:295. Whitmore WF Jr. Symposium of hormones and cancer therapy hormone therapy in prostatic cancer. Am J Med. 1956;21:295.
5.
Zurück zum Zitat Scott R Jr, Mutchnik DL, Laskowski TZ, et al. Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol. 1969;101:602.PubMed Scott R Jr, Mutchnik DL, Laskowski TZ, et al. Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol. 1969;101:602.PubMed
6.
Zurück zum Zitat Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer. 1977;20:680–8.CrossRefPubMed Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer. 1977;20:680–8.CrossRefPubMed
7.
Zurück zum Zitat Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990;143:742–6.PubMed Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990;143:742–6.PubMed
8.
Zurück zum Zitat Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology. 2000;56:3–6.CrossRefPubMed Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology. 2000;56:3–6.CrossRefPubMed
9.
Zurück zum Zitat Platz EA, Smit E, Curhan GC, et al. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancerprostate surgery in US men. Urology. 2002;59:877–83.CrossRefPubMed Platz EA, Smit E, Curhan GC, et al. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancerprostate surgery in US men. Urology. 2002;59:877–83.CrossRefPubMed
10.
Zurück zum Zitat Trueman P, Hood SC, Nayak USL, et al. Prevalence of lower urinary tract symptoms and self-reported diagnosed “benign prostatic hyperplasia,” and their effect on quality of life in a community-based survey of men in the UK. BJU Int. 1999;83:410–15.CrossRefPubMed Trueman P, Hood SC, Nayak USL, et al. Prevalence of lower urinary tract symptoms and self-reported diagnosed “benign prostatic hyperplasia,” and their effect on quality of life in a community-based survey of men in the UK. BJU Int. 1999;83:410–15.CrossRefPubMed
11.
Zurück zum Zitat Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:495–507.PubMed Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:495–507.PubMed
12.
Zurück zum Zitat Fitzpatrick JM. The natural history of benign prostate hyperplasia. BJU Int. 2006;97(Suppl 2):3–6.CrossRefPubMed Fitzpatrick JM. The natural history of benign prostate hyperplasia. BJU Int. 2006;97(Suppl 2):3–6.CrossRefPubMed
13.
Zurück zum Zitat Geller J. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab. 1990;71:1552–5.CrossRefPubMed Geller J. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab. 1990;71:1552–5.CrossRefPubMed
14.
Zurück zum Zitat Crea G, Sanfilippo G, Anastasi G, et al. Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol Int. 2005;74:51–3.CrossRefPubMed Crea G, Sanfilippo G, Anastasi G, et al. Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol Int. 2005;74:51–3.CrossRefPubMed
15.
Zurück zum Zitat Tacklind J, Fink HA, MacDonald R, et al. Finasteride for benign prostatic hyperplasia (Protocol). Cochrane Database Syst Rev. 2009;(3):CD006015. Tacklind J, Fink HA, MacDonald R, et al. Finasteride for benign prostatic hyperplasia (Protocol). Cochrane Database Syst Rev. 2009;(3):CD006015.
16.
Zurück zum Zitat Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–41.CrossRefPubMed Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–41.CrossRefPubMed
17.
Zurück zum Zitat Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64:537–41.CrossRefPubMed Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64:537–41.CrossRefPubMed
18.
Zurück zum Zitat Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. J Urol. 2005;173:515. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. J Urol. 2005;173:515.
19.
Zurück zum Zitat Wilt T, MacDonald R, Hagerty K, et al. Five-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008;(2):CD007091. Wilt T, MacDonald R, Hagerty K, et al. Five-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008;(2):CD007091.
20.
Zurück zum Zitat Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement:2-year results from the CombAT study. J Urol. 2008;179:616–21.CrossRefPubMed Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement:2-year results from the CombAT study. J Urol. 2008;179:616–21.CrossRefPubMed
21.
Zurück zum Zitat Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin:3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur Urol. 1999;36:609–20.CrossRefPubMed Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin:3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur Urol. 1999;36:609–20.CrossRefPubMed
22.
Zurück zum Zitat Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology. 1998;51:901–6.CrossRefPubMed Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology. 1998;51:901–6.CrossRefPubMed
23.
Zurück zum Zitat Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). Br J Urol. 1995;76:325–36.CrossRefPubMed Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). Br J Urol. 1995;76:325–36.CrossRefPubMed
24.
Zurück zum Zitat Narayan P. Tamsulosin: the United States trials. Geriatrics. 1998;53:S29–32.PubMed Narayan P. Tamsulosin: the United States trials. Geriatrics. 1998;53:S29–32.PubMed
25.
Zurück zum Zitat Chapple C, Andersson KE. Tamsulosin: an overview. World J Urol. 2002;19:397–404.PubMed Chapple C, Andersson KE. Tamsulosin: an overview. World J Urol. 2002;19:397–404.PubMed
26.
Zurück zum Zitat Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet. 1991;337(8755):1457–61.CrossRefPubMed Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet. 1991;337(8755):1457–61.CrossRefPubMed
27.
Zurück zum Zitat Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24–30 month survey. Br J Urol. 1994;74:579–84.CrossRefPubMed Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24–30 month survey. Br J Urol. 1994;74:579–84.CrossRefPubMed
28.
Zurück zum Zitat Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology. 2001;58:953–9.CrossRefPubMed Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology. 2001;58:953–9.CrossRefPubMed
29.
Zurück zum Zitat Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet. 1991;338(8760):182. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet. 1991;338(8760):182.
30.
Zurück zum Zitat Vallancien G, Emberton M, Alcaraz A, et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int. 2008;101:847–52.CrossRefPubMed Vallancien G, Emberton M, Alcaraz A, et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int. 2008;101:847–52.CrossRefPubMed
31.
Zurück zum Zitat McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol. 2006;175:35–42.CrossRefPubMed McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol. 2006;175:35–42.CrossRefPubMed
32.
Zurück zum Zitat Takao T, Tsujimura A, Kiuchi H, et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol. 2008;15:992–6.PubMed Takao T, Tsujimura A, Kiuchi H, et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol. 2008;15:992–6.PubMed
33.
Zurück zum Zitat Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019–24.CrossRefPubMed Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019–24.CrossRefPubMed
34.
Zurück zum Zitat Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634–40.CrossRefPubMed Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634–40.CrossRefPubMed
35.
Zurück zum Zitat Merrill RM, Feuer EJ, Warren JL, et al. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol. 1999;150:848–60.PubMed Merrill RM, Feuer EJ, Warren JL, et al. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol. 1999;150:848–60.PubMed
36.
Zurück zum Zitat Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948–54.CrossRefPubMed Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948–54.CrossRefPubMed
37.
Zurück zum Zitat Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–52.CrossRefPubMed Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–52.CrossRefPubMed
38.
Zurück zum Zitat Merrill RM, Potosky AL, Feuer EJ. Changing trends in US prostate cancer incidence rates. J Natl Cancer Inst. 1996;88:1683–5.CrossRefPubMed Merrill RM, Potosky AL, Feuer EJ. Changing trends in US prostate cancer incidence rates. J Natl Cancer Inst. 1996;88:1683–5.CrossRefPubMed
40.
Zurück zum Zitat National Center for Health Statistics. National Hospital Discharge Survey Annual Summary, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006 (machine-readable data file and documentation). Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2007. National Center for Health Statistics. National Hospital Discharge Survey Annual Summary, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006 (machine-readable data file and documentation). Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2007.
41.
Zurück zum Zitat Ries LAG, Kosary CL, Hankey BF, et al., editors. SEER Cancer Statistics Review, 1973–94. NIH Pub. No. 97-2789. Bethesda, MD: National Cancer Institute; 1997. Ries LAG, Kosary CL, Hankey BF, et al., editors. SEER Cancer Statistics Review, 1973–94. NIH Pub. No. 97-2789. Bethesda, MD: National Cancer Institute; 1997.
43.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence—SEER 13 Regs Limited-Use, Nov 2008 Sub (1992–2006) Katrina/Rita Population Adjustment—Linked to County Attributes—Total US, 1969–2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission. Available at: http://www.seer.cancer.gov. Accessed July 24, 2009. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence—SEER 13 Regs Limited-Use, Nov 2008 Sub (1992–2006) Katrina/Rita Population Adjustment—Linked to County Attributes—Total US, 1969–2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission. Available at: http://​www.​seer.​cancer.​gov. Accessed July 24, 2009.
44.
Zurück zum Zitat Kleinbaum DG, Kupper LL, Muller KE 1988 Applied Regression Analysis of Other Multivariable Methods. North Scituate, MA: Duxbury Press, pp 266–8. Kleinbaum DG, Kupper LL, Muller KE 1988 Applied Regression Analysis of Other Multivariable Methods. North Scituate, MA: Duxbury Press, pp 266–8.
45.
Zurück zum Zitat US Department of Health and Human Services. International Classification of Diseases, Ninth Revision. Clinical modification (ICD-9-CM). 3rd ed. DHHS Publication No. (PHS) 89-1260. Hyattsville, MD: US Department of Health and Human Services; 1989. US Department of Health and Human Services. International Classification of Diseases, Ninth Revision. Clinical modification (ICD-9-CM). 3rd ed. DHHS Publication No. (PHS) 89-1260. Hyattsville, MD: US Department of Health and Human Services; 1989.
47.
Zurück zum Zitat Jones JS, Follis HW, Johnson JR. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostatic Dis. 2009;12:57–60.CrossRefPubMed Jones JS, Follis HW, Johnson JR. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostatic Dis. 2009;12:57–60.CrossRefPubMed
48.
Zurück zum Zitat Hoffman RM, Monga M, Elliot SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2007;(4):CD004135. Hoffman RM, Monga M, Elliot SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2007;(4):CD004135.
51.
Zurück zum Zitat Boyle P, Robertson C, Vaughan ED. A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int. 2004;94:83–8.CrossRefPubMed Boyle P, Robertson C, Vaughan ED. A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int. 2004;94:83–8.CrossRefPubMed
52.
Zurück zum Zitat Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–52.CrossRefPubMed Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–52.CrossRefPubMed
53.
Zurück zum Zitat Etzioni R, Gulati R, Falcon S, et al. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making. 2008;28:323–31.CrossRefPubMed Etzioni R, Gulati R, Falcon S, et al. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making. 2008;28:323–31.CrossRefPubMed
Metadaten
Titel
The Diminishing Role of Transurethral Resection of the Prostate
verfasst von
Ray M. Merrill, PhD, MPH
Bradley D. Hunter, BA
Publikationsdatum
01.05.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0896-4

Weitere Artikel der Ausgabe 5/2010

Annals of Surgical Oncology 5/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.